TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19662727
Drug: ProTaper canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProTaper canal preparation and single cone obturation with matching gutta‐percha point
Study: 19662727
Drug: ProTaper preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProTaper preparation plus thermoplastic obturation (Thermafil)
Study: 19662727
Drug: Profile .06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profile .06 taper and matching master cone with lateral condensation
Study: 17931541
Drug: Preprinted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprinted medication labels
Study: 17931541
Drug: Blank medication
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank medication labels
Study: 15355745
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor blocking agents
Study: 3322537
Drug: 6-hydroxybenzo[b]thiophene-2-sulfonamide, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-hydroxybenzo[b]thiophene-2-sulfonamide, 2% suspension, administered twice daily for 1 week to one eye
Study: 3322537
Drug: Placebo drop,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drop, administered twice daily for 1 week to one eye
Study: 22014807
Drug: Toremifene 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 80 mg by mouth daily
Study: 19151449
Drug: Curcumin low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin low dose (3 times 15 mg/day)
Study: 19151449
Drug: Curcumin moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin moderate dose (3 times 30 mg/day)
Study: 19151449
Drug: Curcumin high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin high dose (3 times 60 mg/day)
Study: 19151449
Drug: Curcumin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (all doses)
Study: 16531903
Drug: 2.5 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg.kg(‐1) bw pseudoephedrine
Study: 16531903
Drug: 2.5 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg.kg(‐1) bw maltodextrins (placebo)
Study: 14625607
Drug: Percutaneous hydrochloric
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous hydrochloric acid injection (PHI)
Study: 11084175
Drug: Continuous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regimen of oral conjugated equine estrogens (CEE), 0.625 mg/day, combined with medroxyprogesterone acetate (MPA), 5.0 mg/day
Study: 11084175
Drug: Continuous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regimen of oral conjugated equine estrogens (CEE), 0.625 mg/day, combined with medroxyprogesterone acetate (MPA), 2.5 mg/day
Study: 31047790
Drug: PT followed
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT followed by an increased dose of PT (PT-PT)
Study: 31047790
Drug: CBT followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBT followed by an increased dose of CBT (CBT-CBT)
Study: 28643374
Drug: LY2510924 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2510924 (20 mg once daily)
Study: 28643374
Drug: LY2510924 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2510924 (subcutaneous administration)
Study: 9803103
Drug: 23 G
Normalized name: PEG-23 GLYCERYL DISTEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 G needle
Study: 22951158
Drug: blood‐based crisp
Approvals — FDA: no, EMA: no, PMDA: no
Description: blood‐based crisp bread (35 mg of iron, 27 mg heme Fe)
Study: 22951158
Drug: iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: iron supplementation (35 mg of non‐heme iron/day)
Study: 22951158
Drug: iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: iron supplementation (60 mg of non‐heme iron/day)
Study: 22951158
Drug: control (iron‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (iron‐free tablets)
Study: 21272186
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + pioglitazone 45 mg (n = 12)
Study: 21272186
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy alone (n = 13)
Study: 19039237
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH for 2 years (0.033/0.033 mg/kg/day, n = 51)
Study: 19039237
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH for 1 year and then no treatment for 1 year (0.100/0 mg/kg/day, n = 51)
Study: 19039237
Drug: Mid-dose GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose GH for 1 year (0/0.067 mg/kg/day, n = 47)
Study: 19039237
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of high-dose and low-dose GH after 2 years
Study: 17697905
Drug: SKI306X 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKI306X 200 mg TID
Study: 11986726
Drug: New inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: New inactivated HAV vaccine (1000 units)
Study: 2644795
Drug: Intravenous propafenone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone, 2 mg/kg over 10 minutes
Study: 401600
Drug: Glucagon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (2 mg)
Study: 766062
Drug: Pro‐Banthine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro‐Banthine (45 mg)
Study: 31280348
Drug: High-dose bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bortezomib (1.6 mg/m2) with dexamethasone and cyclophosphamide
Study: 31280348
Drug: Low-dose bortezomib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bortezomib (1.3 mg/m2) with dexamethasone and cyclophosphamide
Study: 31280348
Drug: High-dose bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bortezomib (1.6 mg/m2)
Study: 31280348
Drug: High-dose bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bortezomib (1.6 mg/m2) and low-dose bortezomib (1.3 mg/m2)
Study: 22935739
Drug: Aerobic Interval
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic Interval Training (AIT) with caffeine (3 mg·kg(‐1))
Study: 22935739
Drug: Resting with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resting with caffeine (3 mg·kg(‐1))
Study: 21450707
Drug: Bilateral insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral insertion of 0.20×15 mm Seirin needles to 12 mm depth at ST36, daily treatments of 30 s duration for three consecutive workdays
Study: 17900887
Drug: SFC (S
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (S 50 mcg/FP 250 mcg b.i.d.)
Study: 17900887
Drug: S+FP (S
Approvals — FDA: no, EMA: no, PMDA: no
Description: S+FP (S 50 mcg b.i.d.+FP 250 mcg b.i.d.)
Study: 11985192
Drug: Tooth brushing
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth brushing and 0.2% NaF weekly mouthwashes (Control group, n=33)
Study: 31072314
Drug: EBRT (External
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT (External Beam Radiotherapy) with either 30 Gy in 10 fractions or 8 Gy as a single dose
Study: 26761967
Drug: Nicorandil in
Normalized name: Product containing nicorandil in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil in addition to standard therapy (aspirin, rosuvastatin, valsartan, bisoprolol)
Study: 26761967
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (aspirin, rosuvastatin, valsartan, bisoprolol)
Study: 23317561
Drug: Oral meprednisone
Normalized name: Meprednisone
DrugBank: Meprednisone acetate (DB14625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral meprednisone preoperatively
Study: 23317561
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative systemic steroids)
Study: 22021510
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT examination
Study: 22021510
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT examination (using ICRP 60 tissue-weighting factors)
Study: 22021510
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT examination (using ICRP 103 tissue-weighting factors)
Study: 18835927
Drug: Fluoxetine (6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (6-week administration)
Study: 11278212
Drug: Low-dose step-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose step-up regimen (starting dose 75 IU)
Study: 11278212
Drug: Modified step-down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified step-down regimen (starting dose 300 IU, followed by 3 days free of treatment, then 75 IU daily)
Study: 9042530
Drug: Dim Light‐Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim Light‐Caffeine (200 mg twice each night)
Study: 27651510
Drug: Manipulated high-volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulated high-volume morphine-ADER-IMT (60 mg)
Study: 27651510
Drug: Manipulated low-volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulated low-volume morphine-ADER-IMT (60 mg)
Study: 27651510
Drug: Intact oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact oral morphine-ADER-IMT (60 mg)
Study: 27651510
Drug: Manipulated low-volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulated low-volume morphine ER (60 mg)
Study: 11342682
Drug: lamotrigine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamotrigine (150 mg/day)
Study: 11342682
Drug: carbamazepine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbamazepine (mean 696 mg/day)
Study: 8149032
Drug: 5 milligrams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 milligrams per kilogram per minute of glucose infusion during preoperative overnight fasting
Study: 8149032
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion (control group) during preoperative overnight fasting
Study: 25782429
Drug: Daily fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fruit consumption
Study: 17878479
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg plus docetaxel
Study: 17878479
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg plus docetaxel
Study: 15135147
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500 mg daily for 12 weeks)
Study: 15135147
Drug: Placebo (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1500 mg daily for 12 weeks)
Study: 10690829
Drug: Intraoperative mitomycin‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative mitomycin‐C (0.3 mg/ml) applied under both flaps (group 3)
Study: 10690829
Drug: Intraoperative mitomycin‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the scleral flap (group 2)
Study: 10690829
Drug: Intraoperative mitomycin‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative mitomycin‐C (0.3 mg/ml) applied under the conjunctival flap (group 1)
Study: 9368726
Drug: Simultaneous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous chemotherapy with radiotherapy
Study: 3771854
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin in combination with 0.5% minoxidil
Study: 3771854
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin alone
Study: 29980818
Drug: Cannabis decoction
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis decoction (200 ml)
Study: 29980818
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis oil (1 ml)
Study: 24996447
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) administered one pill a day for 63 days
Study: 24996447
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) plus Dan'e mixture (30 g/day for 30 days)
Study: 22799753
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment administered twice daily for 52 weeks
Study: 20141396
Drug: No antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antidepressant
Study: 18031326
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, 1 mg/m²/day for 12 months
Study: 10834421
Drug: human regular
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: human regular insulin therapy
Study: 10408729
Drug: MN rgp120
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp120 HIV-1 vaccine
Study: 10408729
Drug: IIIB rgp120
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIIB rgp120 HIV-1 vaccine
Study: 8807200
Drug: Priming immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming immunization with IIIB rgp120 followed by booster injections of MN rgp120
Study: 8807200
Drug: MN rgp120
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp120 HIV-1 vaccine given alone
Study: 8807200
Drug: HIV-1IIIB-based gp160
Normalized name: HIV gp160 vaccine
DrugBank: VaxSyn (DB17827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1IIIB-based gp160 vaccines
Study: 4029016
Drug: Temocillin 250
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin 250 mg/h
Study: 4029016
Drug: Temocillin 750
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin 750 mg/h
Study: 4029016
Drug: Probenecid (blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (blocking tubular excretion)
Study: 28353022
Drug: 0.2% morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% morphine
Study: 28353022
Drug: 0.4% morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% morphine
Study: 28353022
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (0.2% morphine, 0.4% morphine, placebo)
Study: 22456699
Drug: Usual practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual practice dysphagia therapy
Study: 19843655
Drug: Perphenazine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (8 to 32 mg daily for 14 to 600 days)
Study: 17506736
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (1 ml of 0.25% bupivacaine on each side)
Study: 17506736
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with pethidine (1 ml of 0.25% bupivacaine and 0.25 mg.kg(‐1) body weight pethidine)
Study: 15652871
Drug: Nocturnal urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal urinary excretion of 6‐sulphatoxymelatonin in patients with autism
Study: 11308250
Drug: DTIC (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4)
Study: 11308250
Drug: DTIC (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC (850 mg/m² every 28 days) plus IFN-alpha2a/b (3 MIU/m², twice on day 1, once daily from days 2 to 5; 5 MIU/m² 3 times a week from week 2 to 4) plus IL-2 (4.5 MIU/m² for 3 hours i.v. on day 3; 9.0 MIU/m² i.v. day 3/4; 4.5 MIU/m² s.c. days 4 to 7)
Study: 9447531
Drug: Surfactant dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant dosing through a proximal sideport adapter
Study: 9447531
Drug: Surfactant dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant dosing through a double-lumen endotracheal tube
Study: 165796
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride treatment
Study: 2405806
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment combined with intensive group psychotherapy
Study: 2405806
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment combined with intensive group psychotherapy
Study: 30824256
Drug: TAU+APP (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU+APP (treatment as usual with app access)
Study: 30824256
Drug: TAU (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (treatment as usual without app access)
Study: 25494297
Drug: Low-iodine-load protocol
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Study: 25494297
Drug: Moderate-iodine-load protocol
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-iodine-load protocol (400 mg iodine per kg at 80 kVp)
Study: 25494297
Drug: High-iodine-load protocol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-iodine-load protocol (600 mg iodine per kg at 120 kVp)
Study: 21299845
Drug: Intravenous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous darbepoetin infusion and intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF (n = 58)
Study: 21299845
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of peripheral blood stem cells mobilized with G‐CSF alone (n = 29)
Study: 21299845
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n = 29)
Study: 16758918
Drug: Chronopuncture as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronopuncture as a non-drug method of arterial pressure correction
Study: 14691440
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (placebo group)
Study: 9154757
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 15 micrograms acetylcholine chloride
Study: 8089668
Drug: Vigabatrin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (1.5 g twice daily)
Study: 3331395
Drug: Dexamethasone 0.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.36 mg/kg/day for 9 days (group S)
Study: 3331395
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group NS)
Study: 25559324
Drug: PegIFN/RBV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN/RBV plus faldaprevir (120 mg, once daily for 12 or 24 weeks) (arm 2)
Study: 25559324
Drug: PegIFN/RBV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN/RBV plus faldaprevir (240 mg, once daily for 12 weeks) (arm 3)
Study: 23007137
Drug: Active stretching
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active stretching program (12 weeks, 3 days/week, 180 seconds daily)
Study: 19205171
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser stimulation treatment (5 mV, 650 nm, 20 minutes daily for 3 months)
Study: 14598939
Drug: ST regimen
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST regimen (streptomycin 1 g/day i.m. for 15 days and tetracycline‐HCl 500 mg every 6 h orally for 45 days)
Study: 14598939
Drug: SD regimen
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days)
Study: 14598939
Drug: DR regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR regimen (doxycycline 100 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Study: 14598939
Drug: OR regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OR regimen (ofloxacin 200 mg every 12 h orally for 45 days and rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Study: 14598939
Drug: SDR regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDR regimen (streptomycin 1 g/day i.m. for 15 days and doxycycline 100 mg every 12 h orally for 45 days plus rifampicin 15 mg/kg per day in a single morning dose orally for 45 days)
Study: 11379605
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose interferon (3 MU day‐1, twice weekly for 6 months)
Study: 7911286
Drug: acrivastine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: acrivastine (8 mg)
Study: 7911286
Drug: terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine (120 mg)
Study: 31345792
Drug: G-CSF-mobilized blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF-mobilized blood stem cell (G-PB) grafts
Study: 26266385
Drug: Argon Plasma
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon Plasma Coagulation (APC) along with distilled water injection
Study: 26266385
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water injection alone